J&J Gets FDA OK of Stelara for Pediatric Patients With Active Psoriatic Arthritis

By Colin Kellaher

Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Monday said the U.S. Food and Drug Administration approved the expanded use of its blockbuster anti-inflammatory drug Stelara to treat children ages six and older with active psoriatic arthritis.

The company said two of the four FDA-approved indications for Stelara now include pediatric patients.

The agency first approved Stelara in September 2009 for adults with moderate to severe plaque psoriasis, and the drug has since been cleared for use in psoriatic arthritis, Crohn's disease and ulcerative colitis.

Johnson & Johnson reported second-quarter Stelara sales of nearly $2.6 billion.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

08-01-22 0951ET